Choose Your Country or Region

Canertinib (CI-1033)

Name: Canertinib (CI-1033)
Brand: Selleck Chemicals
SKU: S1019
Rating: 5 (43 reviews)

Catalog No.S1019 Synonyms: PD183805

For research use only.

Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

CAS No. 267243-28-7

Selleck's Canertinib (CI-1033) has been cited by 43 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Related Compound Libraries

Other EGFR Products

Erlotinib (OSI-774)^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Erlotinib (OSI-774) HCl

Erlotinib (OSI-774, CP358774, NSC 718781) HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.

Download Inhibitor Catalog

EGFR Signaling Pathway Map

Biological Activity

Description

Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

Features

First kinase inhibitor to show irreversible activity and to have entered clinical trials (serving as a template for further development).

Targets

EGFR ^[1] (Cell-free assay)	ErbB2 ^[1] (Cell-free assay)
1.5 nM	9.0 nM

In vitro

CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB 453 cells. CI-1033 also shows high permeability in Caco-2 cells and inhibits secretory transport of vinblastine, which indicates that CI-1033 is a likely inhibitor of the P-gp. ^[1] CI-1033 alone, significantly suppresses constitutively activated Akt and MAP kinase. In combination with gemcitabine, CI-1033 inhibits Akt and prevents increased levels of MAPK phosphorylation. CI-1033 stimulates p27 expression and p38 phosphorylation in MDA-MB-453 cells. ^[2] CI-1033 is highly specific to the erbB receptor family and not sensitive to PGFR, FGFR or IR even at 50 μM. CI-1033 shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM. CI-1033 suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. CI-1033 also inhibits expression of pp62^c-fos in response to heregulin. ^[3] CI-1033 is predicted to modify Cys773 covalently within the ATP binding site of the HER2 kinase and enhances destruction of both mature and immature ErbB-2 molecules. ^[4] CI-1033 induces a significant decrease in measurable phosphorylation of tyrosine residues 845 and 1068 of EGFR, which are responsible for Src and Ras/MAPK signaling respectively. The corresponding residues of Her-2, tyrosine residues 877 and 1248 are dephosphorylated significantly by CI-1033 at a concentration of 3 μM or higher. CI could block EGFR internalization and increase the rate of apoptosis in primary osteosarcoma cells in a titratable fashion. ^[5] In addition, CI-1033 inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM. ^[6]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human HCC827 cells	NWDIOY1lWHKxbHnm[ZJifGmxbjDhd5NigQ>?		MoTHO\|IhcA>?	M2WyUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHTlcEBGPzR4LVG3OVAhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTB;MD6wNFEh\|ryP	MlL3NlI{Ozl\|NEK=
A431 cells	NVLnUGlnTnWwY4Tpc44h[XO\|YYm=			MV;Jcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkBmdnq7bXWgbY4hSTR\|MTDj[YxteyCmZYTlZ5Rm\CCkeTDpcY12dm:kbH;0eIlv\yxiSVO1NF0xNjByN{Sg{txO	NH3wVHoyODd3M{S3OS=>
MDA-MB 453 cells	MYfGeY5kfGmxbjDhd5NigQ>?			Mn3RTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVTSkJ{IILlZ4VxfG:{IHvpcoF{\SCrbjDNSGEuVUJiNEWzJINmdGy\|LDDJR\|UxRTBwMEC5JO69VQ>?	MV[xNFc2OzR5NR?=
human BT474 cells	NIqxcYtRem:uaX\ldoF1cW:wIHHzd4F6		MljsN{Bl[Xm\|	NE\6[oJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXSRoIzKGGodHXyJFMh\GG7czDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZzygSWM2OD1yLkCxJO69VQ>?	M{XmfFE6ODJ6NEK0
mouse BAF3 cells	NUi1NpNDTnWwY4Tpc44h[XO\|YYm=			NGTuRoJKdmirYnn0bY9vKG:oIFLsb{BmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDjfZRwfG:6aXPpeJktKEmFNUC9NE4xOjlizszN	NGqweYcyQDZ4N{OxNi=>
human HN5 cells	M1TOcnBzd2yrZnXyZZRqd25iYYPzZZk>		Ml;FN{Bl[Xm\|	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIHHmeIVzKDNiZHH5d{BjgSCvZYTofYxmdmViYnz1[UB{fGGrbnnu[{whTUN3ME2wMlA2KM7:TR?=	M4jwclE6ODJ6NEK0
human NCI-H1975 cells	NFTLW5ZRem:uaX\ldoF1cW:wIHHzd4F6		MmHxO\|IhcA>?	NEL1b\|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlA3PCEQvF2=	NGXDU2wzOjN\|OUO0Ni=>
human A431 cells	M3uzVnBzd2yrZnXyZZRqd25iYYPzZZk>		NUD5XGlQPzJiaB?=	M3HNd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTB;MD6xOUDPxE1?	NGqzWmQzOjN\|OUO0Ni=>
human A549 cells	M4XmfXBzd2yrZnXyZZRqd25iYYPzZZk>		M2\1SVczKGh?	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgSWdHWiClb3X4dJJme3Orbnegb{1T[XNibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUC9NU42QSEQvF2=	M1nvOFIzOzN7M{Sy
mouse BAF3 cells	MmLTSpVv[3Srb36gZZN{[Xl?			M13ifWlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDjfZRwfG:6aXPpeJnwxIxiSVO1NF0zKM7:TR?=	MmnFNVg3Pjd\|MUK=
human HL7702 cells	NWT3UnM3WHKxbHnm[ZJifGmxbjDhd5NigQ>?		MYK3NkBp	M13KcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy3O\|AzKGOnbHzzJIV5eHKnc4Ppcochf2mudDD0fZBmKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1{LkOg{txO	NX3IcFhUOjJ\|M{mzOFI>
human A431 cells	NFvBdldHfW6ldHnvckBie3OjeR?=	M{PJfFEh\|ryP	NGPY[JMyKGh?	MUXJdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iQUSzNUBk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqIH;1eEBu\WG\|dYLl[EA2KGi{czDwc5N1KEWJRjDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NHLLeYwzPDlyMEW5OC=>
human LNCaP cells	NXXnenZUTnWwY4Tpc44h[XO\|YYm=	M1\ySlExKM7:TR?=	NX\3W4d2OiCq	M3LLVmlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBqdW23bn;wdoVkcXCrdHH0[YQh\myjZz30ZYdo\WRiQn34JIV5eHKnc4Pl[EBqdiCqdX3hckBNVkOjUDDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzNnBeSVSSIHH0JFExKHWPIIDy[ZRz\WG2ZXSg[o9zKDJiaILzJIJm\m:{ZTD0doFve2[nY4Tpc44h[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	MWSxPFY3PzNzMh?=
NCI-H1975 cells	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXS0PEBp	M{nLb2lvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZk>	MUKyOFkxODV7NB?=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Growth inhibition assay	Cell viability	28638122
Western blot	p-FAK / FAK / p-AKT / AKT ; pEGFR / EGFR / p-HER2 / HER2 / p-HER3 / HER3 / MUC4	25686822

In vivo

CI-1033 shows impressive activity against A431 xenografts in nude mice at 5 mg/kg of body weight. ^[1] CI-1033 (20 to 80 mg/kg/d) achieves a high degree of tumor regressions in H125 xenograft models. ^[3] Oral administration of CI-1033 causes a marked inhibition of growth in TT, TE6 and TE10 xenografts in nude mice, without animal death and <10% weight loss. ^[6]

Protocol (from reference)

Kinase Assay:^[1]	Tyrosine Kinase Assays: Enzyme assays for determination of IC50 are performed in 96-well filter plates in a total volume of 0.1 mL, containing 20 mM Hepes, pH 7.4, 50 mM sodium vanadate, 40 mM magnesium chloride, 10 μM adenosine triphosphate (ATP) containing 0.5 mCi of [³²P]ATP, 20 mg of polyglutamic acid/tyrosine, 10 ng of EGFR tyrosine kinase, and appropriate dilutions of CI-1033. All components except the ATP are added to the well and the plate is incubated with shaking for 10 min at 25 °C. The reaction is started by adding [³²P]ATP, and the plate is incubated at 25 °C for another 10 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate is kept at 4 °C for at least 15 min to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL of 10% TCA and 32P incorporation determined with a Wallac β plate counter.
Cell Research:^[6]	Cell lines: TT, TE2, TE6 and TE10 cells Concentrations: 0.1-5.0 nM Incubation Time: 1, 3, 5 and 7 days Method: Cells (1 × 10⁴) are seeded in each well of a 24-well plastic culture plate and left overnight in DMEM or RPMI-1640 supplemented with 10% FBS. The next morning, the cells are treated with the indicated concentrations of CI-1033 (0.1-5.0 nM) for varying periods (1, 3, 5 and 7 days). After treatment, the cells are counted using a Coulter counter. The percent of cell proliferation is calculated by this formula: treatment cell number/control cell number × 100 for each time period.
Animal Research:^[1]	Animal Models: A431 xenografts established in nude mice Dosages: ~18 mg/kg Administration: Administered orally

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 30% propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing. Click to purchase: Tween 80	10 mg/mL

Chemical Information

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	267243-28-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

Download Canertinib (CI-1033) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00050830	Completed	Drug: CI 1033	Lung Neoplasms	Pfizer	January 2003	Phase 2
NCT00174356	Completed	Drug: CI 1033\|Drug: PACLITAXEL\|Drug: CARBOPLATIN	Carcinoma Non-Small Cell Lung	Pfizer	December 2002	Phase 1
NCT00051051	Completed	Drug: CI-1033	Breast Neoplasms	Pfizer	December 2002	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
I would like to know which is the best option/solvent to dilute CI-1033 (Catalog No.S1019) for in vivo experiments. (I am treating mice at 30mg/mL of CI-1033.)

Answer:
The compound in the formulation recommended (30% Propylene glycol, 5% Tween 80, 65% D5W) on our product page at 30mg/ml is suspension. It’s fine for oral gavage.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):